The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)

被引：67

作者：

Fidock, M. D. ^{[1
]}

Souberbielle, B. E. ^{[1
]}

Laxton, C. ^{[1
]}

Rawal, J. ^{[1
]}

Delpuech-Adams, O. ^{[1
]}

Corey, T. P. ^{[1
]}

Colman, P. ^{[1
]}

Kumar, V. ^{[2
]}

Cheng, J. B. ^{[2
]}

Wright, K. ^{[2
]}

Srinivasan, S. ^{[3
]}

Rana, K. ^{[3
]}

Craig, C. ^{[1
]}

Horscroft, N. ^{[1
]}

Perros, M. ^{[1
]}

Westby, M. ^{[1
]}

Webster, R. ^{[1
]}

van der Ryst, E. ^{[1
]}

机构：

[1] Pfizer Ltd, Sandwich Res Labs, Sandwich CT13 9NJ, Kent, England

[2] Pfizer Inc, Groton Res Labs, Groton, CT 06340 USA

[3] Pfizer Inc, Specialty Care Business Unit, New London, CT USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷 / 06期

关键词：

CHRONIC HEPATITIS-C; GENE-EXPRESSION; DENDRITIC CELLS; INTERFERON-ALPHA; VIRUS-INFECTION; THERAPY; TRIAL; BETA; 852A; SUSCEPTIBILITY;

D O I：

10.1038/clpt.2011.60

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hepatitis C virus (HCV) infection is an issue of global concern, and studies are ongoing to identify new therapies that are both effective and safe. PF-4878691 is a Toll-like receptor 7 (TLR7) agonist modeled so as to dissociate its antiviral activities from its inflammatory activities. In a proof-of-mechanism study in healthy volunteers who received doses of 3, 6, and 9 mg of PF-4878691 twice a week for 2 weeks, PF-4878691 induced biomarkers of the immune and interferon (IFN) responses in a dose-dependent and dose-frequency-related manner. A novel finding was induction of TLR7 expression in vivo in response to PF-4878691, leading to an amplified biomarker response. A nonresponder at the 9-mg dose had a polymorphism in the IFN-alpha receptor 1 subunit (Val168Leu). Two subjects who had received 9-mg doses experienced serious adverse events (SAEs), characterized by flu-like symptoms, hypotension, and lymphopenia, leading to early termination of the study. TLR7 stimulation results in a pharmacologic response at levels commensurate with predicted antiviral efficacy, but these doses are associated with SAEs, raising concerns about the therapeutic window of this class of compounds for the treatment of HCV infection.

引用

页码：821 / 829

页数：9

共 33 条

[1] The pharmacology of endosomal TLR agonists in viral disease [J].

Averett, D. R. ;

Fletcher, S. P. ;

Li, W. ;

Webber, S. E. ;

Appleman, J. R. .

BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :1468-1472

[2] Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists [J].

Birmachu, Woubalem ;

Gleason, Raymond M. ;

Bulbulian, Barbara J. ;

Riter, Christie L. ;

Vasilakos, John P. ;

Lipson, Kenneth E. ;

Nikolsky, Yuri .

BMC IMMUNOLOGY, 2007, 8 (1) :1-U18

[3] Regulation of gene expression by pegylated IFN-α2b and IFN-α2b in human peripheral blood mononuclear cells [J].

Brassard, DL ;

Delorenzo, MM ;

Cox, S ;

Leaman, DW ;

Sun, YP ;

Ding, W ;

Gavor, S ;

Spond, J ;

Goodsaid, F ;

Bordens, R ;

Grace, MJ .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2004, 24 (08) :455-469

[4] Managing premedications and the risk for reactions to infusional monoclonal antibody therapy [J].

Chung, Christine H. .

ONCOLOGIST, 2008, 13 (06) :725-732

[5] Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort [J].

Diop, G. ;

Hirtzig, T. ;

Do, H. ;

Coulonges, C. ;

Vasilescu, A. ;

Labib, T. ;

Spadoni, J. -L. ;

Therwath, A. ;

Lathrop, M. ;

Matsuda, F. ;

Zagury, J. -F. .

BIOMEDICINE & PHARMACOTHERAPY, 2006, 60 (09) :569-577

[6] First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agionist, to activate innate immune responses in patients with advanced cancer [J].

Dudek, Arkadiusz Z. ;

Yunis, Caria ;

Harrison, Lester I. ;

Kumar, Sandeep ;

Hawkinson, Ronald ;

Cooley, Sarah ;

Vasilakos, John P. ;

Gorski, Kevin S. ;

Miller, Jeffrey S. .

CLINICAL CANCER RESEARCH, 2007, 13 (23) :7119-7125

[7] An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma [J].

Dummer, Reinhard ;

Hauschild, Axel ;

Becker, Juergen C. ;

Grob, Jean-Jacques ;

Schadendorf, Dirk ;

Tebbs, Veronica ;

Skalsky, Jeannine ;

Kaehler, Katharina C. ;

Moosbauer, Stephanie ;

Clark, Ruth ;

Meng, Tze-Chiang ;

Urosevic, Mirjana .

CLINICAL CANCER RESEARCH, 2008, 14 (03) :856-864

[8] Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1-and Th-17-polarizing capability [J].

Dzopalic, Tanja ;

Dragicevic, Ana ;

Vasilijic, Sasa ;

Vucevic, Dragana ;

Majstorovic, Ivana ;

Bozic, Biljana ;

Balint, Bela ;

Colic, Miodrag .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2010, 10 (11) :1428-1433

[9] Side effects of therapy of hepatitis C and their management [J].

Fried, MW .

HEPATOLOGY, 2002, 36 (05) :S237-S244

[10] Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers [J].

Geller, Melissa A. ;

Cooley, Sarah ;

Argenta, Peter A. ;

Downs, Levi S. ;

Carson, Linda F. ;

Judson, Patricia L. ;

Ghebre, Rahel ;

Weigel, Brenda ;

Panoskaltsis-Mortari, Angela ;

Curtsinger, Julie ;

Miller, Jeffrey S. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (12) :1877-1884

← 1 2 3 4 →